European Markets Move Higher as Growth Fears Remain
By Scott Kanowsky Investing.com -- European markets moved higher on Friday, adding to momentum from a late rally on Wall Street, but sentiment remains cautious as recent economic data...
Strong Buy
or
Sanofi News & Analysis
-
-
European Stock Futures Higher; U.K. Retail Sales Slump
By Peter Nurse Investing.com - European stock markets are expected to open higher Friday, boosted by the previous session’s late rally on Wall Street, but sentiment remains fragile as...
-
Sanofi says COVID-19 vaccine candidate yields positive trial data
PARIS (Reuters) – Sanofi’s COVID-19 vaccine candidate, which is modelled on the virus’s Beta antigen, delivered 72% efficacy in adults against the Omicron strain, the French drugmaker...
-
Aqemia announces extension of its first collaboration with Sanofi on drug discovery in Oncology
This initial collaboration resulted in promising molecules for an oncology program, for which Sanofi and Aqemia decided to pursue joint efforts, the company claims.
-
The Wall Street Journal: COVID-variant booster from Sanofi, GSK shows promising results
A COVID-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of omicron when given as a booster...
-
Covid-19 Variant Shot From Sanofi, GSK Shows Strong Response to Omicron
Results from two new studies are the latest indication that tweaking vaccines can nudge antibody responses in the direction of new variants, possibly helping to shore up immunity as the...
-
Sanofi, GSK say Covid booster shot works better against Omicron variant
The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations.
-
Sanofi's 'next-generation' COVID-19 booster outperformed traditional boosters
Sanofi said Monday that preliminary data shows that its experimental next-generation COVID-19 booster provided a 40-fold increase in antibody protection against BA.1, a subvariant of...
-
European Stocks Sharply Lower; U.K. GDP Slumps in April
By Peter Nurse Investing.com - European stock markets traded lower Monday, with weak UK growth data raising fears of an economic slowdown in the region just as central banks move to address...
-
European Stock Futures Lower; Rate Hike Expectation, COVID Fears Weigh
By Peter Nurse Investing.com - European stock markets are expected to open sharply lower Monday, continuing the global selloff after red-hot inflation data raised fears of aggressive Federal...
-
Sanofi says its COVID-19 booster shot has potential against main variants
PARIS (Reuters) – French drugmaker Sanofi on Monday said the COVID-19 vaccine candidate it has developed jointly with GSK in two trials showed a potential to protect against the virus’s...
-
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi’s (NASDAQ: SNY) lead drug candidate Dupixent (dupilumab) for children aged 6...
-
Sanofi’s Dupixent gets U.S. approval to treat eczema in young children
(Reuters) – The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron Pharmaceuticals Inc’s anti-inflammation drug Dupixent to treat eczema in young children, the...
-
Regeneron buys rights to cancer drug Libtayo from Sanofi
(Reuters) -Regeneron Pharmaceuticals said on Thursday it would buy the global rights to cancer drug Libtayo from French drugmaker Sanofi SA in a deal that includes an upfront payment of $900...
-
Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
Regeneron Pharmaceuticals Inc. announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s stake in the Regeneron-Sanofi collaboration on...
-
Pharma major Sanofi India appoints Preeti Futnani as General Manager, Vaccines
Futnani has over two decades of experience in growth and transformation that spans several therapeutic areas and functions within healthcare and finance.
-
FDA gives Sanofi's experimental hemophilia A drug a Breakthrough Therapy designation
Sanofi said Wednesday that the Food and Drug Administration granted a Breakthrough Therapy designation to the hemophilia A treatment it's developing with Swedish Orphan Biovitrum AB . The...
-
Sanofi India appoints Preeti Futnani as General Manager, Vaccines
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas and functions within healthcare (primary and specialty care, medical...
-
AMC Entertainment, Zoom, Unilever Rise Premarket; American Eagle Outfitters Falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, May 31st. Please refresh for updates. Zoom (NASDAQ:ZM) stock rose 1.6% after Daiwa upgraded its stance on the...
-
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi...
-
Retro Tax: I-T department withdraws Sanofi appeal from Supreme Court
While Sanofi, like many other multinationals, settled this with the taxman under India's plan to rescind the indirect transfer of assets amendment or retrospective tax amendment in December,...
-
Regeneron & Sanofi Get FDA’s Green Light for Dupixent
Co-developed by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY), Dupixent has bagged the U.S. Food and Drug Administration’s approval to treat eosinophilic...
-
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi’s (NASDAQ: SNY) lead drug candidate Dupixent® (dupilumab) 300 mg weekly for...
-
Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects
A French court has ordered Sanofi SA (NASDAQ: SNY) to pay more than €400,000 in damages to a French family whose child had autism caused by its epilepsy drug Valproate. The court mentioned...
-
Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients
Sanofi SA (NASDAQ: SNY) shared the latest results from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in patients with relapsed multiple myeloma receiving a proteasome inhibitor...
-
Sanofi ordered to compensate French family for epilepsy drug side effects
PARIS (Reuters) – A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy...
-
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Arkansas has accused Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and three of the largest pharmacy benefit managers (PBMs) of artificially driving up...
-
DarioHealth Reports Q1 Revenue of $8.06M, Net Loss of $9.9M
DarioHealth Corp. (Nasdaq: NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the first quarter 2022 and provided a corporate and...
-
12 Bluechip Stocks At 52-Week Lows, Should You Buy These Stocks?
It's carnage across the markets with stocks falling across the board. The Sensex has fallen for the 5th straight day. Here are some stocks that have been beaten down.
-
Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)
Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it’s Q1 report. Some of it’s shortfall was attributed by management to longer sales cycles in the insurer and...
-
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Veru Suggested By FDA To Submit Emergency Use Request For Sabizabulin In COVID-19 In a...
-
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV). Results from the...
-
IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi
MOUNTAIN VIEW, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM...
-
Shares in EUROAPI, spun-off from Sanofi, rise on stock market debut
PARIS (Reuters) – Shares in EUROAPI, the drug ingredients business being spun-off by Sanofi, rose on Friday as the company made its debut on the Paris stock market.
-
Sanofi India: Strong balance sheet, high cash reserves positives for stock
Products in the price control list and growth of the non-power brand portfolio will be key monitorables
-
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS) Denali to receive a milestone payment of $40...
-
Buy Sanofi India, target price Rs 9250: Sharekhan by BNP Paribas
Sanofi reported strong results for Q1CY22 with operating margins expanding 139 bps y-o-y and were better than estimated, leading to a PAT ahead of estimates.
-
Sanofi ADR earnings, Revenue beat in Q1
Investing.com - Sanofi (EPA:SASY) ADR reported on Thursday first quarter {{erl-21258||earnings that beat analysts' forecasts and revenue that topped expectations. Sanofi ADR announced...
-
Sanofi earnings, Revenue beat in Q1
Investing.com - Sanofi (EPA:SASY) reported on Thursday first quarter {{erl-414||earnings that beat analysts' forecasts and revenue that topped expectations. Sanofi announced earnings per...
-
European Stock Futures Higher; Corporate Earnings Deluge Continues
By Peter Nurse Investing.com - European stock markets are expected to open higher Thursday as investors await the latest moves in the spat with Russia over gas supplies to Europe while...
-
European Stocks Mixed; Peace Talks, Gas Spat, Eurozone CPI in Focus
By Peter Nurse Investing.com - European stock markets traded in a mixed fashion Friday, with investors cautiously monitoring fresh negotiations aimed at ending the war in Ukraine, the spat...
-
European Stock Futures Largely Flat; Oil Prices Slump on Reserves Release Talk
By Peter Nurse Investing.com - European stock markets are expected to open largely unchanged Thursday at the end of a turbulent month, with investors carefully watching developments in the...
-
IGM Biosciences Shares Rise on Collaboration Agreement with Sanofi
By Sam Boughedda Investing.com -- IGM Biosciences Inc (NASDAQ:IGMS) announced a collaboration agreement with Sanofi (PA:SASY) (NASDAQ:SNY) on Tuesday, causing its shares to...
-
Midday Stock Movers: Nielsen, Robinhood, IGM Biosciences Rise
By Sam Boughedda Investing.com -- U.S. indices are gaining Tuesday on hopes that talks between Ukraine and Russia will result in a ceasefire. Here are the midday movers on Tuesday, March...
-
European Stocks Higher; Ukraine/Russia Peace Talks Boost Sentiment
By Peter Nurse Investing.com - European stock markets traded higher Tuesday with the focus on the start of another round of peace talks between Ukraine and Russia in Turkey. By 4:10 AM ET...
-
European Stock Futures Higher; Ukraine/Russia Peace Talks in Focus
By Peter Nurse Investing.com - European stock markets are expected to open marginally higher Tuesday ahead of the start of another round of peace talks between Ukraine and Russia in Turkey...
-
Sanofi Falls on Trial Setback for Breast Cancer Pill
By Dhirendra Tripathi Investing.com – Sanofi (PA:SASY) (NASDAQ:SNY) ADRs traded 2.5% lower in premarket Monday after an experimental cancer medicine failed to slow progression of a...
-
Sanofi earnings, Revenue beat in Q4
Investing.com - Sanofi (PA:SASY) reported on Friday fourth quarter {{erl-414||earnings that beat analysts' forecasts and revenue that topped expectations. Sanofi announced earnings per...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
